Tuesday, April 21, 2015 3:38:26 PM
I didn't do any kind of comparison to other "enchanced" space company attendees. Hit on "enchanced", it will bring the full list of the others, and then see if they have abstracts. At the time I looked, Abstracts were not in.
When I initially looked at the space they had, and paired it with the ASCO agenda, I really believed they might have been presenting on an entire cancer Designation, as opposed to some sporadic case studies. It could very well be possible that they're done on specific cancers, all the data being in. Maybe there is a reason why AARC abstract only has data for 29 patients assessed in it (29 of the 40 Ph I assessed), and not ONE with Colon in it (unless they were the Several other cancers category). Maybe they're leaving room to showcase the 11 left out of the AARC abstract for an ASCO abstract, but they just haven't annouced it yet. Maybe they'll be a ASCO. SoS seems to believe it might be so. I'm going to be like Flip and wait for it before I say no, but as of today, they're not. :)
When I initially looked at the space they had, and paired it with the ASCO agenda, I really believed they might have been presenting on an entire cancer Designation, as opposed to some sporadic case studies. It could very well be possible that they're done on specific cancers, all the data being in. Maybe there is a reason why AARC abstract only has data for 29 patients assessed in it (29 of the 40 Ph I assessed), and not ONE with Colon in it (unless they were the Several other cancers category). Maybe they're leaving room to showcase the 11 left out of the AARC abstract for an ASCO abstract, but they just haven't annouced it yet. Maybe they'll be a ASCO. SoS seems to believe it might be so. I'm going to be like Flip and wait for it before I say no, but as of today, they're not. :)
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
